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In this issue of Blood, Gertz and colleagues present a retrospective study that analyzes progression-free 
survival and overall survival in 286 patients comparing those who did not reach a partial response or 
progressed during induction therapy with a regimen including thalidomide or lenalidomide to those who 
did achieve at least a partial response.  
In multiple myeloma patients, the role of induction treatment before high-dose therapy and stem cell 
transplantation has been unclear. For many years, the administration of induction therapies with 
conventional chemotherapy did not improve the outcome of patients receiving high-dose therapy and 
autologous transplantation. Both progression-free survival and overall survival were not significantly 
different between patients sensitive or refractory to induction with conventional therapy.1,2 This treatment 
paradigm has been changed by the availability of novel agents, such as thalidomide, lenalidomide, and 
bortezomib. With conventional chemotherapy, the partial response rate after induction therapy was 
around 50% and complete responses were quite rare. Treatment regimens using these novel agents report 
partial response rates ranging from 80% to 100%, and complete response from 20% to 40%.3 
The outcome of the 286 patients studied by Gertz et al compared patients who did achieve a partial 
response during induction therapy with those who did not. The median overall survival after autologous 
transplantation was 73.5 months in patients who achieved a partial response and 30.4 months in those 
who did not (P < .0005). Similarly, median progression-free survival was 22.1 months in responders to 
induction and 13.1 months in nonresponders (P < .0001).4 The authors of this article conclude that the lack 
of response during induction therapy or the progression, despite a short initial response during induction 
therapy, predict a poor outcome for patients receiving high-dose therapy and autologous transplantation.  
In many studies, the achievement of response, in particular the achievement of complete response or very 
good partial response, has been considered a strong predictor of outcome, especially for patients 
undergoing autologous stem cell transplantation. In a recent study, both 5-year event-free survival and 5-
year overall survival rates were significantly increased in patients achieving at least very good partial 
response after autologous transplantation. Unfortunately, this response marker is only available at the end 
of the entire treatment procedure including both induction and autologous transplantation.5 The value of 
the finding of Gertz et al lies in the possibility of using a response marker in the early phases of therapy, 
allowing a better modulation of treatment choice immediately after the first courses of induction therapy. 
Other markers equally predict a poor outcome and the need for a more intense treatment approach. The 
most useful are advanced clinical stage such as the International Staging System 3 or chromosomal 
abnormalities, such as t(4;14), t(14;16), and del(17). Suboptimal response in the early phases of treatment 
may represent an advantage over biological markers for the treatment choice of an individual patient.  
A suboptimal response might influence physicians' decisions on prolongation of induction therapy from 3 to 
6 cycles. It might suggest an increasing of the potency of the induction regimen, moving from a 2-drug 
combination to a 3-drug combination that includes an additional agent, either novel agents or doxorubicin 
or cyclophosphamide. The advantage of a tandem, instead of a single, transplantation in patients with 
suboptimal response after induction therapy or in those with less than complete response after the first 
transplantation should be considered. Few data are available on the role of consolidation and maintenance 
therapy after autologous stem cell transplantation. But similarly, the expectation of poor outcome 
predicted by suboptimal response after induction therapy might suggest the introduction of a consolidation 
approach after autologous transplantation, such as bortezomib-cyclophosphamide-dexamethasone, 
bortezomib-lenalidomide-dexamethasone, or bortezomib-thalidomide-dexamethasone combination.6 
Maintenance therapy is an alternative strategy. Three different phase 3 studies found that thalidomide 
maintenance improved progression-free and overall survival. Lenalidomide may offer the same advantage 
with less toxicity7 and large randomized trials are now addressing its role in the posttransplantation setting. 
More recently, data on bortezomib maintenance are also showing efficacy in this setting.  
Further studies are needed to assess the role of tailored therapies in patients with poor outcome. The study 
presented by Gertz et al clearly shows that patients who do not reach at least partial response after 
induction therapy will do considerably worse and different treatment approaches are needed. Whether 
intensification of induction, use of tandem transplantation, introduction of consolidation, or maintenance 
therapy are the appropriate choices to overcome poor outcome still remains an open question. Despite 
this, in newly diagnosed patients, it is reasonable to use all available options to improve suboptimal 
responses.  
On the other hand, we should avoid the risk of undertreating patients with good tumor reduction after 
induction therapy or autologous transplantation. In a recent analysis, only patients who achieved at least 
very good partial response after autologous stem cell transplantation received a consolidation with the 3-
drug combination, bortezomib-thalidomide-dexamethasone. In these good-prognosis patients, the addition 
of consolidation after transplantation improved the complete response rate from 15% after transplantation 
to 50% after consolidation. The absence of a consolidation approach in patients with very good partial 
response after transplantation may significantly decrease the possibility to achieve a complete response.8 
In good-prognosis patients, the best treatment option, validated by large phase 3 studies, should be always 
considered to maximize the chance of a profound tumor reduction and a prolonged remission duration. In 
patients with poor prognosis, a more intense approach should be offered. The lack of a partial response 
after induction therapy with novel agents should now be considered another sign of poor prognosis and 
should suggest an intensification of the reference treatment.  
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